<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216108</url>
  </required_header>
  <id_info>
    <org_study_id>S61408</org_study_id>
    <nct_id>NCT04216108</nct_id>
  </id_info>
  <brief_title>Comparative Study 23G Versus 27G Vitrectomy</brief_title>
  <acronym>23Gvs27G</acronym>
  <official_title>Comparative Study 23G Versus 27G Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Peter Stalmans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator-initiated, comparative double-arm, mono-center, prospective, interventional case
      study to determine whether ultra-small gauge surgery (27G gauge needle) improves
      postoperative outcome and patient morbidity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">March 13, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in post-operative outcome of pain</measure>
    <time_frame>1 week</time_frame>
    <description>By assessing the amount of pain on a visual analogue scale (score 0 - 9)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in post-operative outcome of redness</measure>
    <time_frame>1 week</time_frame>
    <description>Scoring the amount of redness on a scale 0-4 through eye photos</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in post-operative outcome of measured inflammation</measure>
    <time_frame>1 week</time_frame>
    <description>Measuring the amount of inflammation by measurement of Flare (photon/ms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in post-operative outcome in grading of anterior chamber cells</measure>
    <time_frame>1 week</time_frame>
    <description>Clinical assesment by slit lamp (Tyndall 0 - 3 and Cells 0 - 3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative parameter: Visual acuity</measure>
    <time_frame>1 week</time_frame>
    <description>Best corrected visual acuity in LogMar will be obtained to report the visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative parameter: Intraocular pressure</measure>
    <time_frame>1 week</time_frame>
    <description>Millimeter of Mercury pressure (mmHG) will be measured to report the intraocular pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative parameter: Pain assessment</measure>
    <time_frame>1 week</time_frame>
    <description>A questionnaire with visual analogue scale will be used to assess the level of pain up to 1 week after the operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Vitreoretinal Surgery</condition>
  <arm_group>
    <arm_group_label>23G gauge needle vitrectomy surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>27G gauge needle vitrectomy surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitrectomy (23G gauge needle)</intervention_name>
    <description>Vitrectomy surgery with 23G gauge needle technique</description>
    <arm_group_label>23G gauge needle vitrectomy surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitrectomy (27G gauge needle)</intervention_name>
    <description>Vitrectomy surgery with 27G gauge needle technique</description>
    <arm_group_label>27G gauge needle vitrectomy surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged over 18

          -  No prior vitrectomy surgery in the study eye

          -  No prior inclusion in this trial

          -  Scheduled for vitrectomy for floater removal or macular surgery

        Exclusion Criteria:

          -  Patients with serious heart, lung, liver, or kidney dysfunction

          -  Patients with proliferative diabetic retinopathy, endophthalmitis, uveitis and other
             eye disease that impacts the outcome of vitrectomy surgery Patients with HIV (Human
             Immune-deficiency Virus)

          -  Patients with history of drug abuse or alcoholism

          -  Patients participating in other drug or medical device clinical trials before
             screening for this trial

          -  Pregnancy, preparation for pregnancy during clinical trial, or breastfeeding

          -  Belief by the investigator that a patient's condition would hinder the clinical trial,
             such as a patient prone to mental stress, loss of control of mood, or depression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Stalmans, MD Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven (UZ Leuven)</name>
      <address>
        <city>Leuven</city>
        <state>Vl-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Peter Stalmans</investigator_full_name>
    <investigator_title>Prof. Dr. Peter Stalmans</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

